Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Celle – page 52

724 clinical trials in Celle, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Celle at a glance
724
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

724 trials in Celle

Open in trial search

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Caplacizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Study on Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer Not Treatable by Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Celgene Corp.

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Lupus nephritis

Not recruiting

Study on the Effectiveness and Safety of Iptacopan with Drug Combination for Adults with Active Lupus Nephritis Class III-IV, +/- V

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Celle

What the registry says about research in the country

01 Breast Cancer Research

Clinical studies focusing on triple-negative breast cancer and HER2-negative breast cancer, evaluating innovative treatment approaches in both early and advanced stages of the disease.

  • Advanced Treatment Protocols
  • Chemotherapy Combinations
  • Hormone Receptor Studies

Investigations combining immunotherapy with traditional chemotherapy regimens, aiming to improve survival rates and treatment outcomes for breast cancer patients.

02 Immunotherapy Research

Groundbreaking studies exploring the effectiveness of atezolizumab in combination with established chemotherapy protocols for breast cancer treatment.

  • Neoadjuvant Therapy
  • Adjuvant Treatment
  • Event-Free Survival Analysis

Research focusing on measuring survival rates and analyzing treatment response patterns in advanced breast cancer patients.

03 Molecular Patterns Analysis

Comprehensive research investigating spatial and temporal patterns in breast cancer treatment responses, with particular focus on drug efficacy and resistance mechanisms.

  • Treatment Resistance Studies
  • Progression-Free Survival
  • Overall Survival Analysis

Studies examining therapeutic outcomes in hormone receptor-positive breast cancer patients undergoing first-line treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.